Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krech

Showing results (351-360 of 470) with videos related to

Pageof 47
Sort By:
Critical Pathways in Cardiology|November 16, 2016
Chest Pain Risk Scores Can Reduce Emergent Cardiac Imaging Test Needs With Low Major Adverse Cardiac Events Occurrence in an Emergency Department Observation UnitHao Wang, Katherine Watson, Richard D Robinson, et al.
Cancer Investigation|June 18, 2021
Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer AggressivenessSören Weidemann, Daniel Perez, Jakob R Izbicki, et al.
International Journal of Molecular Sciences|April 21, 2015
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomyMaria Christina Tsourlakis, Puya Khosrawi, Philipp Weigand, et al.
Carcinogenesis|September 23, 2015
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersNathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, et al.
Urologic Oncology|May 12, 2015
Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibilityJonas Schiffmann, Philipp Wenzel, Georg Salomon, et al.
Oncotarget|April 1, 2015
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomyCristina Villares Zabalza, Meike Adam, Christoph Burdelski, et al.
Plos One|June 2, 2015
Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate CancersChristoph Burdelski, Erzen Bujupi, Maria Christina Tsourlakis, et al.
BMC Cancer|November 14, 2018
Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcomeKatharina Grupp, Bianca Hofmann, Asad Kutup, et al.
Breast Cancer (Tokyo, Japan)|October 9, 2021
6q deletion is frequent but unrelated to patient prognosis in breast cancerPatrick Lebok, Hannah Bönte, Martina Kluth, et al.
Oncotarget|March 13, 2015
Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancerChristoph Burdelski, Christian Strauss, Maria Christina Tsourlakis, et al.
Pageof 47

Showing results (351-360 of 470) with videos related to

Sort By:
Pageof 47
Critical Pathways in Cardiology|November 16, 2016
Chest Pain Risk Scores Can Reduce Emergent Cardiac Imaging Test Needs With Low Major Adverse Cardiac Events Occurrence in an Emergency Department Observation UnitHao Wang, Katherine Watson, Richard D Robinson, et al.
Cancer Investigation|June 18, 2021
Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer AggressivenessSören Weidemann, Daniel Perez, Jakob R Izbicki, et al.
International Journal of Molecular Sciences|April 21, 2015
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomyMaria Christina Tsourlakis, Puya Khosrawi, Philipp Weigand, et al.
Carcinogenesis|September 23, 2015
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersNathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, et al.
Urologic Oncology|May 12, 2015
Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibilityJonas Schiffmann, Philipp Wenzel, Georg Salomon, et al.
Oncotarget|April 1, 2015
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomyCristina Villares Zabalza, Meike Adam, Christoph Burdelski, et al.
Plos One|June 2, 2015
Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate CancersChristoph Burdelski, Erzen Bujupi, Maria Christina Tsourlakis, et al.
BMC Cancer|November 14, 2018
Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcomeKatharina Grupp, Bianca Hofmann, Asad Kutup, et al.
Breast Cancer (Tokyo, Japan)|October 9, 2021
6q deletion is frequent but unrelated to patient prognosis in breast cancerPatrick Lebok, Hannah Bönte, Martina Kluth, et al.
Oncotarget|March 13, 2015
Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancerChristoph Burdelski, Christian Strauss, Maria Christina Tsourlakis, et al.
Pageof 47